A quinoline-based DNA methyltransferase inhibitor as a possible adjuvant in osteosarcoma therapy

Maria Cristina Manara, Sergio Valente, Camilla Cristalli, Giordano Nicoletti, Lorena Landuzzi, Clemens Zwergel, Roberta Mazzone, Giulia Stazi, Paola B. Arimondo, Michela Pasello, Clara Guerzoni, Piero Picci, Patrizia Nanni, Pier Luigi Lollini, Antonello Mai, Katia Scotlandi

Research output: Contribution to journalArticle

Abstract

The identification of new therapeutic strategies against osteosarcoma, the most common primary bone tumor, continues to be a primary goal to improve the outcomes of patients refractory to conventional chemotherapy. Osteosarcoma originates from the transformation of mesenchymal stem cells (MSC) and/or osteoblast progenitors, and the loss of differentiation is a common biological osteosarcoma feature, which has strong significance in predicting tumor aggressiveness. Thus, restoring differentiation through epigenetic reprogramming is potentially exploitable for therapeutic benefits. Here, we demonstrated that the novel nonnucleoside DNMT inhibitor (DNMTi) MC3343 affected tumor proliferation by blocking osteosarcoma cells in G1 or G2–M phases and induced osteoblastic differentiation through the specific reexpression of genes regulating this physiologic process. Although MC3343 has a similar antiproliferative effect as 5azadC, the conventional FDA-approved nucleoside inhibitor of DNA methylation, its effects on cell differentiation are distinct. Induction of the mature osteoblast phenotype coupled with a sustained cytostatic response was also confirmed in vivo when MC3343 was used against a patient-derived xenograft (PDX). In addition, MC3343 displayed synergistic effects with doxorubicin and cisplatin (CDDP), two major chemotherapeutic agents used to treat osteosarcoma. Specifically, MC3343 increased stable doxorubicin bonds to DNA, and combined treatment resulted in sustained DNA damage and increased cell death. Overall, this nonnucleoside DNMTi is an effective novel agent and is thus a potential therapeutic option for patients with osteosarcoma who respond poorly to preadjuvant chemotherapy.

Original languageEnglish
Pages (from-to)1881-1892
Number of pages12
JournalMolecular Cancer Therapeutics
Volume17
Issue number9
DOIs
Publication statusPublished - Sep 2018

Fingerprint

Methyltransferases
Osteosarcoma
DNA
Osteoblasts
Doxorubicin
Therapeutics
Drug Therapy
Neoplasms
Cytostatic Agents
DNA Methylation
Mesenchymal Stromal Cells
Nucleosides
Heterografts
Epigenomics
Cisplatin
DNA Damage
quinoline
Cell Differentiation
Cell Death
Phenotype

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A quinoline-based DNA methyltransferase inhibitor as a possible adjuvant in osteosarcoma therapy. / Manara, Maria Cristina; Valente, Sergio; Cristalli, Camilla; Nicoletti, Giordano; Landuzzi, Lorena; Zwergel, Clemens; Mazzone, Roberta; Stazi, Giulia; Arimondo, Paola B.; Pasello, Michela; Guerzoni, Clara; Picci, Piero; Nanni, Patrizia; Lollini, Pier Luigi; Mai, Antonello; Scotlandi, Katia.

In: Molecular Cancer Therapeutics, Vol. 17, No. 9, 09.2018, p. 1881-1892.

Research output: Contribution to journalArticle

Manara, Maria Cristina ; Valente, Sergio ; Cristalli, Camilla ; Nicoletti, Giordano ; Landuzzi, Lorena ; Zwergel, Clemens ; Mazzone, Roberta ; Stazi, Giulia ; Arimondo, Paola B. ; Pasello, Michela ; Guerzoni, Clara ; Picci, Piero ; Nanni, Patrizia ; Lollini, Pier Luigi ; Mai, Antonello ; Scotlandi, Katia. / A quinoline-based DNA methyltransferase inhibitor as a possible adjuvant in osteosarcoma therapy. In: Molecular Cancer Therapeutics. 2018 ; Vol. 17, No. 9. pp. 1881-1892.
@article{b1748d8a81bb4f2a9e00e680834a7597,
title = "A quinoline-based DNA methyltransferase inhibitor as a possible adjuvant in osteosarcoma therapy",
abstract = "The identification of new therapeutic strategies against osteosarcoma, the most common primary bone tumor, continues to be a primary goal to improve the outcomes of patients refractory to conventional chemotherapy. Osteosarcoma originates from the transformation of mesenchymal stem cells (MSC) and/or osteoblast progenitors, and the loss of differentiation is a common biological osteosarcoma feature, which has strong significance in predicting tumor aggressiveness. Thus, restoring differentiation through epigenetic reprogramming is potentially exploitable for therapeutic benefits. Here, we demonstrated that the novel nonnucleoside DNMT inhibitor (DNMTi) MC3343 affected tumor proliferation by blocking osteosarcoma cells in G1 or G2–M phases and induced osteoblastic differentiation through the specific reexpression of genes regulating this physiologic process. Although MC3343 has a similar antiproliferative effect as 5azadC, the conventional FDA-approved nucleoside inhibitor of DNA methylation, its effects on cell differentiation are distinct. Induction of the mature osteoblast phenotype coupled with a sustained cytostatic response was also confirmed in vivo when MC3343 was used against a patient-derived xenograft (PDX). In addition, MC3343 displayed synergistic effects with doxorubicin and cisplatin (CDDP), two major chemotherapeutic agents used to treat osteosarcoma. Specifically, MC3343 increased stable doxorubicin bonds to DNA, and combined treatment resulted in sustained DNA damage and increased cell death. Overall, this nonnucleoside DNMTi is an effective novel agent and is thus a potential therapeutic option for patients with osteosarcoma who respond poorly to preadjuvant chemotherapy.",
author = "Manara, {Maria Cristina} and Sergio Valente and Camilla Cristalli and Giordano Nicoletti and Lorena Landuzzi and Clemens Zwergel and Roberta Mazzone and Giulia Stazi and Arimondo, {Paola B.} and Michela Pasello and Clara Guerzoni and Piero Picci and Patrizia Nanni and Lollini, {Pier Luigi} and Antonello Mai and Katia Scotlandi",
year = "2018",
month = "9",
doi = "10.1158/1535-7163.MCT-17-0818",
language = "English",
volume = "17",
pages = "1881--1892",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - A quinoline-based DNA methyltransferase inhibitor as a possible adjuvant in osteosarcoma therapy

AU - Manara, Maria Cristina

AU - Valente, Sergio

AU - Cristalli, Camilla

AU - Nicoletti, Giordano

AU - Landuzzi, Lorena

AU - Zwergel, Clemens

AU - Mazzone, Roberta

AU - Stazi, Giulia

AU - Arimondo, Paola B.

AU - Pasello, Michela

AU - Guerzoni, Clara

AU - Picci, Piero

AU - Nanni, Patrizia

AU - Lollini, Pier Luigi

AU - Mai, Antonello

AU - Scotlandi, Katia

PY - 2018/9

Y1 - 2018/9

N2 - The identification of new therapeutic strategies against osteosarcoma, the most common primary bone tumor, continues to be a primary goal to improve the outcomes of patients refractory to conventional chemotherapy. Osteosarcoma originates from the transformation of mesenchymal stem cells (MSC) and/or osteoblast progenitors, and the loss of differentiation is a common biological osteosarcoma feature, which has strong significance in predicting tumor aggressiveness. Thus, restoring differentiation through epigenetic reprogramming is potentially exploitable for therapeutic benefits. Here, we demonstrated that the novel nonnucleoside DNMT inhibitor (DNMTi) MC3343 affected tumor proliferation by blocking osteosarcoma cells in G1 or G2–M phases and induced osteoblastic differentiation through the specific reexpression of genes regulating this physiologic process. Although MC3343 has a similar antiproliferative effect as 5azadC, the conventional FDA-approved nucleoside inhibitor of DNA methylation, its effects on cell differentiation are distinct. Induction of the mature osteoblast phenotype coupled with a sustained cytostatic response was also confirmed in vivo when MC3343 was used against a patient-derived xenograft (PDX). In addition, MC3343 displayed synergistic effects with doxorubicin and cisplatin (CDDP), two major chemotherapeutic agents used to treat osteosarcoma. Specifically, MC3343 increased stable doxorubicin bonds to DNA, and combined treatment resulted in sustained DNA damage and increased cell death. Overall, this nonnucleoside DNMTi is an effective novel agent and is thus a potential therapeutic option for patients with osteosarcoma who respond poorly to preadjuvant chemotherapy.

AB - The identification of new therapeutic strategies against osteosarcoma, the most common primary bone tumor, continues to be a primary goal to improve the outcomes of patients refractory to conventional chemotherapy. Osteosarcoma originates from the transformation of mesenchymal stem cells (MSC) and/or osteoblast progenitors, and the loss of differentiation is a common biological osteosarcoma feature, which has strong significance in predicting tumor aggressiveness. Thus, restoring differentiation through epigenetic reprogramming is potentially exploitable for therapeutic benefits. Here, we demonstrated that the novel nonnucleoside DNMT inhibitor (DNMTi) MC3343 affected tumor proliferation by blocking osteosarcoma cells in G1 or G2–M phases and induced osteoblastic differentiation through the specific reexpression of genes regulating this physiologic process. Although MC3343 has a similar antiproliferative effect as 5azadC, the conventional FDA-approved nucleoside inhibitor of DNA methylation, its effects on cell differentiation are distinct. Induction of the mature osteoblast phenotype coupled with a sustained cytostatic response was also confirmed in vivo when MC3343 was used against a patient-derived xenograft (PDX). In addition, MC3343 displayed synergistic effects with doxorubicin and cisplatin (CDDP), two major chemotherapeutic agents used to treat osteosarcoma. Specifically, MC3343 increased stable doxorubicin bonds to DNA, and combined treatment resulted in sustained DNA damage and increased cell death. Overall, this nonnucleoside DNMTi is an effective novel agent and is thus a potential therapeutic option for patients with osteosarcoma who respond poorly to preadjuvant chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85053014459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053014459&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-17-0818

DO - 10.1158/1535-7163.MCT-17-0818

M3 - Article

AN - SCOPUS:85053014459

VL - 17

SP - 1881

EP - 1892

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 9

ER -